GHP Family Pharmacy Customer Service 100 N. Academy Ave. Danville, PA 17822 Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com



## OCALIVA (obeticholic acid) PRIOR AUTHORIZATION FORM (form effective 01/05/2021)

Prior authorization guidelines for **Bile Salts and Quantity Limits/Daily Dose Limits** are available on Geisinger Health Plan's website at https://bealthplan.geisinger.org/pharmacy/aspx?strin\_true&style\_OneGeisinger

website at <a href="https://neaith">https://neaith</a>	<u>bian.geisinger.org/phan</u>	пасу/рпагтасу.а	<u> = Strip: xqsv</u>	true&style=OneGelsinger		
□ New request □ Renewal request Total # pages:		Prescriber name:				
Name of office contact:		Specialty:				
Phone number of office contact:		NPI:		MA Provider ID#:		
LTC facility contact/phone:		Street address:				
Beneficiary name:		Suite #:	City/state/zip	//state/zip:		
Beneficiary ID#: DOB:		Phone: Fax:				
CLINICAL INFORMATION						
Drug requested: Ocaliva tablet		Quantity:				
Directions:		Refills:				
Diagnosis:			Dx code (required):			
Specialty Pharmacy Drug Program: Ocaliva is part of the DHS Specialty Pharmacy Drug Program and is only available from one of the two DHS specialty pharmacies – Walgreen's Specialty Pharmacy.						
INITIAL Ocaliva requests     Is Ocaliva prescribed by or in consultation with a hepatologist or gastroenterologist?			Yes– Submit documentation of consultation.			
2. Does the beneficiary have a diagnosis of primary biliary cholangitis (PBC)?  Yes- Submit documentation of lab results and medical history supporting diagnosis.  No- Submit documentation supporting the use of Ocaliva for beneficiary's diagnosis.						
3. Does the beneficiary have results of the following baseline (before starting Ocaliva) lab results?  AST GGTP bilrubin HDL-C ALT alkaline phosphatase INR			☐ Yes- Submit results and dates of all lab monitoring for all requested values. ☐ No			
<ol> <li>Does the beneficiary have a history of therapeutic failure of optimally titrated doses of ursodeoxycholic acid (UDCA)?</li> </ol>			☐ Yes— Submit all supporting documentation of trial and failure (including doses tried), contraindications, or intolerances with ursodiol. ☐ No			
5. Will the beneficiary be taking Ocaliva in combination with UDCA?			☐ Yes ☐ No	No		
6. Does the beneficiary have a contraindication or intolerance to UDCA?			☐ Yes ☐ No			
7. Does the beneficiary have documentation of the following lab results since starting Ocaliva and within the past 6 months?  AST GGTP billrubin HDL-C  ALT alkaline phosphatase INR			☐ Yes- Submit results and dates of all lab monitoring for all requested values. ☐ No			
8. Is there medical record documentation of a positive clinical response to Ocaliva, as evidenced by liver function test?			Yes – Submit results of liver function tests showing positive results  No			
9. Does the beneficiary have complete bili	-		☐ Yes ☐ No	Submit documentation of clinical		
lease submit to PromptPA https://ghp		to Geisinger Head all documentation		: 570-271-5610 the complete	ed form with	
Prescriber Signature				Date:		